During the COVID-19 pandemic L’Eau dramatically escalated the production of Nemesis eH2O; making it available in hospitals, care homes and over 2,000 high-street stores in the UK, for example. Launched just before the COVID outbreak, Nemesis eH2O offered customers far superior disinfection performance, when compared with traditional disinfectants.
As a powerful anti-viral, broad spectrum disinfectant; highly effective against viruses, bacteria and fungi, Nemesis eH2O contains stabilised hypochlorous acid (HOCl). It contains no harmful chemicals or alcohol, so no personal protective equipment (PPE) is necessary for normal use.
According to the World Health Organization (WHO), out of every 100 patients in acute-care hospitals, seven patients in high-income countries and 15 patients in low- and middle-income countries will acquire at least one HAI during their hospital stay, and on average, 1 in every 10 affected patients will die from their HAI.
The COVID-19 pandemic highlighted the extent to which health care settings can contribute to the spread of infections; harming patients, health workers and visitors if insufficient attention is paid to infection prevention and control (IPC). In a recent report, the WHO showed that where good IPC practices are followed, 70% of those infections can be prevented.
